%0 Journal Article
%T A Nonimmunosuppressant Approach on Asia Psoriasis Subjects: 5-Year Followup and 11-Year Data Analysis
%A Tony Yuqi Tang
%J Dermatology Research and Practice
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/304172
%X Mono- or combine immunosuppressants are commonly used for psoriasis; however the side effect caused by potent systemic immunosuppressants frequently incurred; moreover the inflammation flares up shortly after immunosuppressants are discontinued. An alternative nonimmunosuppressive therapy was introduced to psoriasis subjects. A retrospective observational study consisted of 1583 psoriasis patients who were treated with Herose Psoria capsule 1440£¿mg three times daily at two clinical centres, one in China, the other in Singapore, from 1 January 2000 to 1 January 2011. Psoriasis lesion evolution was photographed at monthly visit, and efficacy and safety were assessed using psoriasis area severity index PASI score grading, renal and liver function testing, and adverse event reporting and supplemented by information obtained during targeted telephone interviews. The effectiveness of Herose on psoriasis was inversely associated to prior immunosuppressants exposure ( ), significant improvements occurred in non-immunosuppressants subjects, and complete clearance was achieved in 8 months (87.5%, 14 of 16); the wavelike evolution of psoriatic lesion appeared in prior immunosuppressants subjects. 1. Introduction Psoriasis is quite common; its prevalence ranges from 0.6% to 4.8% and shows a wide variability among ethnic groups [1]. The estimated prevalence of psoriasis is 0.123% in China, and there have been more than 3 million cases reported since 1984 [2]. In Singapore, psoriasis affects 1% to 2% of the population. Clinical manifestation of psoriasis is heterogeneous, ranging from limited to extensive. Guttate psoriasis is often a self-limited disease, lasting from 12 to 16 weeks without treatment [3]. It has been estimated that one-third to two-thirds of these patients later develop the chronic plaque type of psoriasis [4]; however, chronic plaque psoriasis is in most cases a lifelong disease and reported to wax and wane over time with episode of remissions and exacerbations [5], manifesting at unpredictable intervals. Erythrodermic and generalized pustular psoriasis have a poorer prognosis, with the disease tending to be severe and persistent [3]. Dermatological pathogenesis and medicine are ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required, previously psoriasis had been viewed as primarily a disease of hyperproliferation, and more recently it has come to be regarded as an autoimmune-mediated disease; hence the conventional systemic immunosuppressive (Corticosteroids, PUVA,
%U http://www.hindawi.com/journals/drp/2012/304172/